Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia.
about
The β-Lactams Strike Back: Ceftazidime-AvibactamCommunity-acquired pneumonia: identification and evaluation of nonrespondersPharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient PopulationsThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemVentilator-associated pneumonia: diagnosis, treatment, and preventionIndividualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumoniaPharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumoniaAntibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Optimizing antibiotic treatment for ventilator-associated pneumonia.Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects.Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia.Overview of antimicrobial therapy in intensive care units.Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.Ceftazidime for respiratory infections.Delivering antibiotics to the lungs of patients with ventilator-associated pneumonia: an update.The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies.Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis.Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulationsContinuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendationContinuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?Determination of meropenem penetration into the lung from Sparse data.Comparison of continuous infusion with intermittent bolus administration of cefotaxime on blood and cavity fluid drug concentrations in neonatal foals.Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection.Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens.Ceftazidime improves hemodynamics and oxygenation in ovine smoke inhalation injury and septic shock.Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
P2860
Q26796425-70346E01-18CA-4668-93E1-3A516DFAAE2CQ27002420-BD11E70A-87E4-41EA-9838-543EB934E1AEQ28066877-5F6AE176-B290-497D-BB19-2B6A82BC96CCQ28289744-53308897-D5FD-45C9-8E9D-C72D43B1DC5CQ29012676-29FFFDD1-1FFC-412D-85E4-63211E56A10CQ34274190-8A9983DF-514E-4AEF-99A3-63F56EF37D1BQ34737703-63E2ED79-B66F-466D-BCEF-86989F928A4CQ35168955-07D2DB51-78EA-4C7A-B0AB-0F2BB222074FQ35169028-0234F81D-DF43-4954-B384-CCCE81330BABQ35908084-F1B10849-3C05-44B3-B4B1-8330C2877C60Q36083619-38F200BA-5E91-494F-AE7E-4C30E7C830C9Q36390901-33C2D080-30C3-46C0-B548-E32B73570814Q37274678-380C585E-87A3-42A2-92E8-022A597E354BQ37287884-7A184DF2-3CF1-4711-9FC3-03FD8C585F52Q37643614-ECD521C0-5BF6-45E4-B9F3-A96E58EF32D9Q37643682-A3C56230-3569-4328-8989-092D7A48C13FQ37822457-2F8A840A-E401-4791-9C80-AFA5ABDA0838Q37927017-4EACCCE6-E831-4362-872B-09F0EF973DF0Q38040144-CFFFAC93-9DF6-49E9-B138-5CE8EFCAD1C1Q38102781-4AABCC52-1128-44C2-AA41-BC5E9314C62FQ38837353-7E3F73B0-6D0B-4EA2-8D48-2C889CC6AC80Q38850670-02750FD2-506D-4175-89EB-B3C1C9F8717FQ39586044-FF37AA12-B0AA-45A9-9EDE-21E06827D829Q42006135-A5A16D23-6C05-49BA-B499-87313ABFE137Q42203839-94F9D6D3-C94D-469E-8D04-8A2A309077C0Q42432137-8F5E0504-4491-48A3-9CC1-5B89BF61DC5EQ43005046-1A0F25E7-82D5-4F24-B596-68F0B2D6EDFCQ44557053-C914BECF-0D2B-4F85-AF68-4E87294B4A7AQ46857071-233007B2-77A5-4BD9-93E1-75D51B2FB949Q51616538-216D4F6E-AA25-46E6-B3A6-E321E40A8EECQ51753265-52E1FEAD-E488-4949-9E5D-160D74215DAEQ58701649-09EA4DEC-6A53-4B3A-8394-1D73B0E0BF37
P2860
Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Plasma and lung concentrations ...... h severe nosocomial pneumonia.
@en
Plasma and lung concentrations ...... h severe nosocomial pneumonia.
@nl
type
label
Plasma and lung concentrations ...... h severe nosocomial pneumonia.
@en
Plasma and lung concentrations ...... h severe nosocomial pneumonia.
@nl
prefLabel
Plasma and lung concentrations ...... h severe nosocomial pneumonia.
@en
Plasma and lung concentrations ...... h severe nosocomial pneumonia.
@nl
P2093
P1476
Plasma and lung concentrations ...... h severe nosocomial pneumonia.
@en
P2093
Bernard Allaouchiche
Dominique Breilh
Dominique Chassard
Jean-Charles Poupelin
Marie-Claude Saux
Thomas Rimmelé
P2888
P304
P356
10.1007/S00134-004-2171-2
P577
2004-02-24T00:00:00Z